Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report) Director James Tananbaum bought 140,000 shares of the stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the director owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Latigo Biotherapeutics Trading Up 1.7%
Latigo Biotherapeutics stock traded up $0.31 during trading hours on Monday, hitting $18.56. The stock had a trading volume of 598,445 shares. Latigo Biotherapeutics, Inc. has a one year low of $17.22 and a one year high of $22.47.
Featured Articles
- Five stocks we like better than Latigo Biotherapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
